Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The bifunctional enzyme
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4
(PFKFB4) controls metabolic flux through allosteric regulation of glycolysis. Here we show that
p53
regulates the expression of PFKFB4 and that
p53
-deficient cancer cells are highly dependent on the function of this enzyme. We found that
p53
downregulates PFKFB4 expression by binding to its promoter and mediating transcriptional repression via histone deacetylases. Depletion of PFKFB4 from
p53
-deficient cancer cells increased levels of the allosteric regulator fructose-2,6-bisphosphate, leading to increased glycolytic activity but decreased routing of metabolites through the oxidative arm of the pentose-phosphate pathway. PFKFB4 was also required to support the synthesis and regeneration of nicotinamide adenine dinucleotide phosphate (NADPH) in
p53
-deficient cancer cells. Moreover, depletion of PFKFB4-attenuated cellular biosynthetic activity and resulted in the accumulation of reactive oxygen species and cell death in the absence of
p53
. Finally, silencing of PFKFB4-induced apoptosis in
p53
-deficient cancer cells in vivo and interfered with tumour growth. These results demonstrate that PFKFB4 is essential to support anabolic metabolism in
p53
-deficient cancer cells and suggest that inhibition of PFKFB4 could be an effective strategy for cancer treatment.
...
PMID:6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells. 2809 78